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ABSTRACT
Protein–ligand interaction analysis is an important
step of drug design and protein engineering in order
to predict the binding affinity and selectivity between
ligands to the target proteins. To date, there are more
than 100 000 structures available in the Protein Data
Bank (PDB), of which ∼30% are protein–ligand (MW
below 1000 Da) complexes. We have developed the
integrative web server MANORAA (Mapping Analo-
gous Nuclei Onto Residue And Affinity) with the aim
of providing a user-friendly web interface to assist
structural study and design of protein–ligand inter-
actions. In brief, the server allows the users to input
the chemical fragments and present all the unique
molecular interactions to the target proteins with
available three-dimensional structures in the PDB.
The users can also link the ligands of interest to as-
sess possible off-target proteins, human variants and
pathway information using our all-in-one integrated
tools. Taken together, we envisage that the server will
facilitate and improve the study of protein–ligand in-
teractions by allowing observation and comparison
of ligand interactions with multiple proteins at the
same time. (http://manoraa.org).
INTRODUCTION
Understanding protein–ligand interaction is crucial for
drug discovery research, as it defines the binding affinity,
steric complementarity of the surface and pharmacophoric
patterns of the compound to the target protein. Favor-
able ligand interactions with protein such as suitable polar
groups counterparts and proper hydrogen bonding partners
are crucial for the ligand design process and the imperfect fit
between the protein and the ligand will result in decreased
binding affinity (1). A number of tools is available for visu-
alizing and analyzing protein–ligand interaction; however,
only few can provide comprehensive information such as
verified binding affinity, and couple the results with the lig-
and interaction visualization available for multiple protein
comparison in the same place (2). By understanding the fa-
vorable interactions between the target protein and a ligand
of interest, one can start to rationalize drug design strategy
and make the protein engineering possible by strengthening
preferred interactions for instance.
To date, there are more than 100 000 structures in the
Protein Data Bank (PDB) (3). However, it is not always
straightforward to harness all the relevant information from
the PDB. Querying the substructure of the ligands to re-
turn multiple molecular interactions that are available in
the PDB can take a considerable amount of time as one
normally goes through a series of non-intuitive steps. After
multiple protein–ligand structures are retrieved, the com-
parison can be complicated and time-consuming, especially
when the structures contain a large amount of protein–
ligand interactions from multiple contacts points, which
normally have to be investigated individually and manually.
To the best of our knowledge, there is no existing tool specif-
ically designed for comparative analysis of protein–ligand
interactions in multiple structures at the time.
Two of the most popular tools for searching molecular
interactions in the binding sites are Relibase (4) and PDBe-
Motif (5). Both tools are restricted to the structures in the
PDB and are often used to show the distribution of protein–
ligand binding patterns in the PDB as a whole. Other tools
such as PLIP (6) are also available for investigating protein
*To whom correspondence should be addressed. Tel: +66 2 441 9003 (Ext. 1211); Fax: +66 2 9428499; Email: duangrudee.tan@mahidol.ac.th
C© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
Nucleic Acids Research, 2016, Vol. 44, Web Server issue W515
ligand interactions and visualization; however, the users
cannot obtain knowledge of preferred interactions easily
because it is dedicated to visualization and does not allow
sorting by binding affinities, or viewing multiple proteins
structures that bind to the same ligand in the same panel.
The PLIC database (7) provides protein–ligand interaction
clusters and also other related binding site information, and
also has a superposition panel based on the clustering of
similar binding sites. However, the ligand superposition is
performed as a whole molecule, not based on the equiva-
lent substructures, and hence, it is difficult to directly re-
late that information to the change in the binding affinities.
WONKA (8) on the other hand, can offer observation from
multiple structures but it requires the users to supply the set
of superposed proteins with their equivalent amino acids re-
named to the corresponding residue numbers. PoSSuM (9)
aims to detect similar small molecule binding pockets; how-
ever, the overall similarity between pockets do not guaran-
tee the same ligand binding pattern. A tool such as PLI (10)
can also be used to find a particular ligand binding to a list
of homologous proteins.
A direct query of ligand to the RCSB Protein Data Bank
(3,11) returns the data retrieval in the form of PDB files and
Jmol applet but does not provide ligand substructure anal-
yses for multiple structures. The databases BindingDB (12)
and Binding MOAD (13) emphasize the binding affinities
data for further use such as for QSAR analysis (14), which
does not offer the structural analysis of the binding site or
the trend of binding affinity. In addition, these databases do
not provide links from fragments to pathways or known hu-
man variants such as SNPs, a feature that will be useful for
the drug design in the personalized medicine era.
To this end, we have developed the integrative web server
MANORAA (Mapping Analogous Nuclei Onto Residue
And Affinity) to facilitate understanding of ligand selectiv-
ity and promiscuity through the analysis of multiple pro-
tein structures on the web interface. It enables researchers
to retrieve multiple chemical compounds and their binding
partner proteins from the PDB, and compare and visual-
ize the ligand-residue contact interactions all at the same
time. Other useful functionalities include sorting of bind-
ing affinities of multiple proteins, as well as obtaining ad-
ditional information such as protein functions, the species
that a particular ligand is found in a complex, and the path-
ways that the ligand is found to take part in by linking to a
pathway map such as KEGG (15), all in one place.
MANORAA: rationales, input and output
We built MANORAA with an aim to provide a user-
friendly, one-stop service for ligand–protein interaction
investigation. MANORAA was developed on top of
CREDO, a database devoted specially to the protein–ligand
interaction, which provides all pairwise atomic interaction
contacts between ligand and proteins from the PDB in the
form of a relational database (16,17). By filtering and rank-
ing the interaction types in a systematic manner, the ligand
contacts that are most important can be shown and can be
related to the change in the binding affinities. This server
provides integrated information about the target and off-
target proteins interacting with the query ligand from the
latest publicly available mirror of CREDO. MANORAA
also provides protein–ligand binding affinity values from
the Binding MOAD database (13) where the high qual-
ity binding affinity data are collected from literature. Im-
portantly, the users can observe and compare the interac-
tion by processing the ligand contact with multiple protein
structures based on the complexes deposited to the PDB
all at the same time. All queries to MANORAA start from
one simple input page, and the results are provided in two
output steps, as described here. We have extensively tested
MANORAA on several common operating systems and
web browsers (see Supplementary Data for details), and the
most compatible browsers that we recommend areWindows
version 7 or higher, and OSX Maverick or higher, and on
Chrome 49 or higher, and Safari 9 or higher.
Input: chemical structure
The users can start with a ligand or part of a ligand of inter-
est by providing one of the following as an input: (i) chemi-
cal name, (ii) SMILES expression, (iii) PDB ligand’s 3-letter
code or (iv) chemical structure (Figure 1). To facilitate gen-
eration of a SMILES expression, theMANORAAprovides
the SMILES lookup and then exports the SMILES to the
chemical sketch panel as shown in Figure 1. The users can
also select to create or edit a SMILES expression by draw-
ing a chemical structure, or modify some parts and then
import that sketch to a SMILES string before submission.
From SMILES, the users can link to extended ligand names
and compound bioactivity information via ChEMBL (18).
The web server employs a JavaScript library called Marv-
inJS from ChemAxon to achieve the task. MarvinJS pro-
vides an HTML5-based user interface for chemical draw-
ing, which allows the users to have an interactive interface
without the need to install any additional plug-in.
Output 1: list of proteins interacting with a queried ligand
Once the users submit a ligand, a list of PDB entries that
contain the submitted ligand will be returned. Ligand(s)
of similar chemical structure and their target proteins will
be returned if any part of the molecule matches with the
SMILES input fragment. For example, Figure 2 shows a
table of PDB entries interacting with a ligand ‘STU’ (Stau-
rosporine). The binding affinity values, taken from Bind-
ing MOAD (13), are provided to help prioritize target
proteins as they imply the binding strengths between the
query ligand and the targets. For each entry, the follow-
ing external information is also provided: (i) the pathway
information from KEGG (15), (ii) the protein informa-
tion from UniProt (19), (iii) the amino acid variants from
SAMUL (20) and (iv) variants, isoforms and genomic con-
text, protein/RNAbaseline expression, gene ontology from
theCentre for Therapeutic Target Validation (OpenTargets,
https://www.targetvalidation.org/). The server links crystal-
lographic structures of protein–ligand interaction to related
biochemical pathways via UniProt ID to KEGG ID map-
ping. The user can also link the proteins of interest to known
human variants such as SNPs in the coding regions via the
SAMULweb server (20). This essentially allows researchers
to predict whether the candidate ligands will have a ten-
dency to bind proteins with different annotated SNPs in the
W516 Nucleic Acids Research, 2016, Vol. 44, Web Server issue
Figure 1. Input panel for ligand fragment via chemical names, SMILES expression, PDB ligand’s three-letter code or chemical structure drawing.
coding regions, an important step of drug design in the per-
sonalized medicine era. These results can be exported as a
CSV table.
This result page serves as an input form for the next
step, which is to visualize three-dimensional (3D) structures
of protein–ligand interactions based on the selection of (i)
atomof interest in the ligand, and (ii) the target PDB chains.
To aid this process, the MANORAA web server shows the
ligand chemical structure so that users can pick up atoms of
their interest interactively. By default, all the heteroatoms of
ligands and PDB chains where the binding affinity are avail-
able are pre-selected.
Output 2: visualization of ligand–protein interactions
Once the users select ligand atoms and associated protein
chains of interest, MANORAA will connect to CREDO
to obtain interacting partner proteins of each ligand and
PDB pair, grouped by nine interaction types and high-
light them by different colors. The available interaction
types are aromatic, hydrogen bond, ionic interaction, co-
valent bond, metal complex, carbonyl interaction, halogen
bond, hydrophobic interaction and van der Waals clash (as
shown in Figure 3 with criteria in Supplementary Data).
The server will then rank the most important contact based
on the shortest distances of unique interaction found for ev-
ery atom per amino acid residue. JSmol (21), a JavaScript
framework based on HTML5 for displaying interactive 3D
molecular structures, has been employed into the user inter-
face to enable the users to toggle display of the interaction
partners in the 3D viewing panel. Display of ligand–protein
interaction at each residue can be obtained by clicking the
loading button of each PDB IDs, then choosing the residue
name of interest. This step allows the user to have full con-
trol on what part of the chemical structure that they want to
focus on. The results can be revisited using a unique URL
provided. The list of target proteins and contact residues
can be printed as PDF file together with the protein struc-
tures which can be saved from JSmol. Note that additional
technical details of the web server can be found as Supple-
mentary Data.
To assist the first-time users, we have provided compre-
hensive step-by-step tutorial, demo video and sample pages
on the web server. Here, we also provide two examples
of how MANORAA can be employed to assist real-world
drug design and protein engineering research.
Making use of MANORAA in ligand–protein interaction
studies
Case study 1: the trend of interaction observed in N4 of STU
interacting with the kinase family. To illustrate the use of
MANORAA and its features, here we use our previous
comprehensive study on staurosporine’s binding strength
as an example (22). The study demonstrated that stau-
rosporine’s strength of interaction with kinase depends on
the number and the orientation of hydrogen bonds and ionic
interactions made around the N4 atom of staurosporine.
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Figure 2. MANORAA provides integrated analyses for ligand–protein interactions, linking structural biology to genomics, pathways and target informa-
tion. Middle inset: the ligand panel on the left shows a chemical fragment with information of their protein binding partners on the right. This allows users
to make a query on their molecular interactions with available binding affinity, and obtain additional information about the target proteins/genes. Top left:
target gene information such as baseline expression is provided via the Open Targets project, using UniProt name. Top right: link to the protein structure
information via PDBe. Bottom left: SNP information via SAMUL. Bottom right: KEGG pathway where the protein/gene of interest is highlighted. The
results can be sorted by the proteins’ name, resolution, binding affinity and can be saved to a CSV file on the top of the page as needed.
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Figure 3. Display of the ligand three-letter code STU (staurosporine) interacting with several proteins in the kinase family. The top row shows interaction
with the lowest binding affinity value, which means staurosporine can tightly bind (0.00033 M) via aspartate, and there are at most two hydrogen bonds
(cyan) or ionic interaction (magenta) in combination. The second group has binding affinity values between 0.0065 to 0.010 Mand has three interactions
that are either ionic or hydrogen bonds. All the others with binding affinity value more than 0.010 M have one hydrogen bond, or ionic interaction, or
no interaction at all.
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For the worst STU binding to kinase cases, N4 from PDB
IDs: 1XBC, 1U59, 3HMO have only one bond in the non-
preferable orientation while the one from 1Q3D does not
have any hydrogen bonding or ionic interaction at all. These
two structural observations imply poor binding affinity and
hence they are present in the group of large binding affin-
ity values. In contrast, 1OKY, 1NVR, 1STC and 1YHS
have better binding affinities due to better hydrogen bond-
ing and ionic interaction in both the structural orientation
sense and also the amount of bonds they made which are at
least two hydrogen bonds plus one ionic interaction. Note
that binding via aspartatemakes the interaction tighter than
binding via arginine as seen in 1XJD and 2Z7R and hence
shown with the lowest Ki or tightest binding affinities from
the Binding MOAD database. These types of analysis will
be beneficial to drug design because we know which part of
the ligand is the major determinant of the binding affinities
andwhat amino acids facilitate those preferred interactions.
With MANORAA, these processes can be performed all in
one place (Figure 3).
Case study 2: howMANORAA can be powerful for analyzing
ligand and its binding protein with known SNPs that can be
linked to diseases. Trifluoperazine (PDB ligand code TFP)
was originally identified as an antipsychotic drug used in
the treatment of schizophrenia, via blocking D2 dopamin-
ergic receptors in the brain. However, trifluoperazine has re-
cently been repurposed to inhibit the growth of cancer stem
cells via its function as a calmodulin inhibitor, but the in-
hibitorymechanism is unclear (23,24). UsingMANORAA,
we can demonstrate that this ligand can also bindwithmany
target proteins such as the placental calcium binding pro-
tein (S100-A4), calmodulin and troponin C (in a way, ‘off-
targets’ to dopaminergic receptors). The result shows that
the N3 atom of TFP interact with the placental calcium
binding protein (S100-A4) via one hydrogen bond, or one
optional ionic interaction in the cases of bovine calmodulin
and human troponin C, suggesting the importance of this
atom for all the proteins that bind to this small molecule.
On the other hand, the N2 atom of TFP forms two ionic in-
teractions with both bovine calmodulin structures but does
not make any significant interaction for either S100-A4 pro-
tein or human troponin C. This kind of information can be
useful for designing the selectivity of the drug.
Furthermore, MANORAA (via SAMUL) also reveals
two SNPs in the human calmodulin gene that have been
associated with ventricular tachycardia, a common side ef-
fect from trifluoperazine use. MANORAA also provides
a list of multiple bovine calmodulin with crystallographic
structures that harbor the ligand, enabling researchers to
explore the effect of amino acid changes to affect ligand–
protein interaction. This demonstrates how MANORAA
can be used for an initial assessment of drug repurposing
results. It should be noted that our data relies on crystallo-
graphic structures deposited to the PDB at the time. Saying
that, MANORAA provides another way to make use of the
growing PDB by linking the structures to human genome
variations.
DISCUSSION AND FUTURE DIRECTIONS
Thanks to technological advances in crystallography and
other methods for determining structures of biological
molecules, the bottleneck of structural biology is now shift-
ing from obtaining the structures to interpreting and link-
ing them to other biological information such as path-
ways and genomic variants. With the wealth of informa-
tion on ligand–protein interactions from publicly available
databases such as PDB, it is now possible to perform a com-
parative study ofmultiple ligands and proteins (or drug can-
didate compounds and target proteins) at the same time.
MANORAA has been established to facilitate these pro-
cesses all in one place.
The web server has a number of useful features that as-
sist the investigation of ligand–protein binding specificity,
biological pathways the proteins are involved in and known
human variants in the coding regions of the proteins. As de-
picted by Bo¨hm, ligand with poor binding affinity is caused
by missing crucial active site interactions in comparison
with other tight binding ligands (1). Our service allows the
user to compare the ligand’s binding affinities with the num-
bers and the types of interactions that the ligandmakes with
multiple proteins, which should be useful for users to iden-
tify the key residues of proteins and the atoms of ligands in
order to manipulate the interaction strength.
Existing protein–ligand contact and interaction
databases are required in order to expedite the pro-
cess of calculating and classifying the molecular interaction
on the fly. To this end, we make use of the CREDO
backend, and provide links to SAMUL (20), UniProt
(19), PDBe (5), PDBsum (25) and KEGG (15). Note
that the total size of calculated interaction for CREDO
databases alone, including all the structures in the PDB, is
very large (72 GB), but that would allow the interactions
to be observed almost instantaneously. The graphical
representation on JSmol (21) allows the users to view
multiple structures with the fragment in the same window.
The color highlight of the protein–ligand interaction that
links to the JSmol structure visualization panel in real-time
allows robust ligand interaction identification so that the
researchers can relate the knowledge of the binding affinity
value to the missing or occurring interaction by themselves.
MANORAA employs a support responsive design, which
means the output structures can be visualized without
distortion even on a tablet or mobile phone. Another
unique feature of MANORAA is its multiple-structures
visualization panel with multiple loading buttons. The
users can observe multiple structures one at a time and
progress to each one to get an impression of the whole
set of proteins that interact with this particular ligand
fragment, and could identify the amino acid residue or
atoms of a ligand that can be modified to fine-tune the
ligand–protein binding interaction.
The main strengths of MANORAA over other previ-
ously available web servers aforementioned includes its flex-
ibility of analyzing multiple experimentally verified ligand–
protein interactions at the time, using its user-friendly and
fast responsive interface. PLIP (6), for instance, focuses on
the visualization of one structure at a time, while PoSSuM
(9) provides the superposition and makes a comparison be-
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tween residues surrounding a protein pair, rather than giv-
ing details of the type of residues in contact. Even though
there are a number of tools that allow multiple structure
observation, the interactions are not dissected to different
chemical interaction types and do not provide visualization
panel for the users to drill down to the level of ligand sub-
structure interactions.
Looking ahead, we aim to routinely maintain the server
and add new functionalities, which will be managed by a
programmer dedicated to MANORAA’s development and
a multidisciplinary team. For instance, we have been devel-
oping a new algorithm to show gradient color of atomic
position conservation. This will allow us to show position-
specific interaction by highlighting the active site based on
the percent conservation of the atomic position surround-
ing the ligand substructure. For the time being, we have
implemented this for 18 staurosporine superposed com-
plexes as an example from our sample page (see Supple-
mentary Data). In addition, protein ligand contacts will be
updated for every newer release of CREDO. In addition,
PDBe (5), PDBsum (25), CACTVS (26,27), ChEMBL (18),
KEGG (15), Open Targets (https://www.targetvalidation.
org/), UniProt (19) and SAMUL (20) are accessed in real-
time through their websites, hence the results shown will al-
ways be the most updated.
With MANORAA, the chemical fragments that have an
influence on different pathways in different organisms can
open the door for a more robust and insightful analysis
for the study of multi-target drug design, species selectiv-
ity, off-target inhibition causing drug side effect problems.
We envisage that MANORAA will provide a missing link
between structural biology, systems biology and genetics in-
formation by one central concept surrounding the ligand’s
chemical structure to assist drug discovery and the probe
molecules community.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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